Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02660034
Title	The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	BeiGene
Indications	stomach cancer ovary epithelial cancer pancreatic adenocarcinoma Advanced Solid Tumor fallopian tube cancer prostate cancer ureter cancer peritoneum cancer lung small cell carcinoma renal pelvis carcinoma invasive bladder transitional cell carcinoma gastroesophageal junction adenocarcinoma transitional cell carcinoma triple-receptor negative breast cancer
Therapies	Pamiparib + Tislelizumab
Age Groups:	adult \| senior
Covered Countries	USA \| NZL \| GBR \| FRA \| ESP \| AUS